Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19)
A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the globe since December 2019. Coronavirus disease 2019 (COVID-19) has a significantly higher mortality rate than seasonal influenza and has disproportionately affected older adults, especially those with cardiovascular disease and related risk factors. Adverse cardiovascular sequelae, such as myocarditis, acute myocardial infarction, and heart failure, have been reported in patients with COVID-19. No established treatment is currently available; however, several therapies, including remdesivir, hydroxychloroquine and chloroquine, and interleukin (IL)-6 inhibitors, are being used off-label and evaluated in ongoing clinical trials. Considering these therapies are not familiar to cardiovascular clinicians managing these patients, this review describes the pharmacology of these therapies in the context of their use in patients with cardiovascular-related conditions.
| Errataetall: |
CommentIn: J Vasc Surg. 2020 Aug;72(2):756-757. - PMID 32417015 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
Journal of cardiovascular pharmacology - 75(2020), 5 vom: 01. Mai, Seite 359-367 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dixon, Dave L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 19.05.2020 Date Revised 11.11.2023 published: Print CommentIn: J Vasc Surg. 2020 Aug;72(2):756-757. - PMID 32417015 Citation Status MEDLINE |
|---|
| doi: |
10.1097/FJC.0000000000000836 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308675428 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308675428 | ||
| 003 | DE-627 | ||
| 005 | 20231225132234.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/FJC.0000000000000836 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1028.xml |
| 035 | |a (DE-627)NLM308675428 | ||
| 035 | |a (NLM)32282502 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dixon, Dave L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19) |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.05.2020 | ||
| 500 | |a Date Revised 11.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: J Vasc Surg. 2020 Aug;72(2):756-757. - PMID 32417015 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the globe since December 2019. Coronavirus disease 2019 (COVID-19) has a significantly higher mortality rate than seasonal influenza and has disproportionately affected older adults, especially those with cardiovascular disease and related risk factors. Adverse cardiovascular sequelae, such as myocarditis, acute myocardial infarction, and heart failure, have been reported in patients with COVID-19. No established treatment is currently available; however, several therapies, including remdesivir, hydroxychloroquine and chloroquine, and interleukin (IL)-6 inhibitors, are being used off-label and evaluated in ongoing clinical trials. Considering these therapies are not familiar to cardiovascular clinicians managing these patients, this review describes the pharmacology of these therapies in the context of their use in patients with cardiovascular-related conditions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Van Tassell, Benjamin W |e verfasserin |4 aut | |
| 700 | 1 | |a Vecchié, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Bonaventura, Aldo |e verfasserin |4 aut | |
| 700 | 1 | |a Talasaz, Azita H |e verfasserin |4 aut | |
| 700 | 1 | |a Kakavand, Hessam |e verfasserin |4 aut | |
| 700 | 1 | |a D'Ascenzo, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Perciaccante, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Castagno, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Ammirati, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Biondi-Zoccai, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Stevens, Michael P |e verfasserin |4 aut | |
| 700 | 1 | |a Abbate, Antonio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cardiovascular pharmacology |d 1990 |g 75(2020), 5 vom: 01. Mai, Seite 359-367 |w (DE-627)NLM000951579 |x 1533-4023 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2020 |g number:5 |g day:01 |g month:05 |g pages:359-367 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/FJC.0000000000000836 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2020 |e 5 |b 01 |c 05 |h 359-367 | ||